



Inimex Selected as One of the Top 10 Life Sciences Corporate Investment and Partnering Prospects in Canada

Vancouver, B.C., Canada – September 18, 2002 – Inimex Pharmaceuticals, Inc., is pleased to announce that it has been selected as one of the Top-10 Investment and Partnering Prospects in the Canadian biotechnology sector.

Inimex was selected by an international panel based on an evaluation of its science & technology platform and the commercial potential of its product development portfolio. Selected Companies are divided into two categories: Early Stage Companies (1st and 2nd Round Financing Opportunities) and Emerging and Later Stage Companies (Mezzanine and Later Stage Opportunities). Inimex is one of five companies selected in the Early Stage Category.

As part of the award, Jeffrey Bacha, President & CEO of Inimex will make a presentation to an audience of potential investors and corporate partners at the upcoming BioNorth 2002 Conference, which will be held at the Ottawa Congress Center in Ottawa, Canada November 4 – 6, 2002.

“This is important recognition for Inimex. We are pleased that the selection jury recognized the broad commercial potential of our technology platform and the significant opportunity to develop new medicines for infectious diseases based on the enhancement of innate immunity,” said Jeffrey Bacha, President & CEO of Inimex Pharmaceuticals Inc.

Inimex Pharmaceuticals Inc.

Inimex Pharmaceuticals, Inc. is a Vancouver B.C. based private biopharmaceutical company dedicated to the discovery, development and commercialization of new medicines based on the up-regulation and control of the innate immune response. For additional information, please visit the company's website, www.inimexpharma.com, or contact info@inimexpharma.com.

Earlier this year, Inimex announced that the Company had established an exclusive relationship with Genome Canada through the \$27million Functional Pathogenomics of Mucosal Immunity (FPMI) program, which supports Inimex's functional genomics and bio-informatics infrastructure. Under the agreement, Inimex will receive research funding and exclusive commercial rights to any human healthcare related discoveries made under the program.

To date, Inimex has identified a novel class of peptides that increase the production of particular elements of innate immunity in vivo, without inducing an inflammatory/sepsis response. These compounds are currently being advanced into specific models of infectious disease as potential lead candidates.